Intravenous administration of mononuclear UCB cells, including CD14+ monocytes, 48 h post-stroke led to a significant reduction in infarct size and promoted functional recovery in contrast to CD14+-monocyte-depleted controls [171]. Here, CD14 is linked to stroke disorder.